Please login to the form below

Not currently logged in
Email:
Password:

oritavancin

This page shows the latest oritavancin news and features for those working in and with pharma, biotech and healthcare.

Actavis gets FDA nod for new antibiotic

Actavis gets FDA nod for new antibiotic

dalbavancin) and The Medicine Company's Orbactiv (oritavancin).

Latest news

  • Antibiotics among 7 new drugs backed by EMA Antibiotics among 7 new drugs backed by EMA

    Both The Medicines Company's Orbactiv (oritavancin) and Cubist's Sivextro (tedizolid phosphate) were among seven new medicines backed by EMA scientific advisers in the Committee for Medicinal Products for Human

  • FDA backs Cubist's antibiotic Zerbaxa FDA backs Cubist's antibiotic Zerbaxa

    In addition to Sivextro, the agency also gave a green light this year to Durata Therapeutics' Dalvance (dalbavancin) - recently acquired by Actavis - and The Medicines Company's Orbactiv (oritavancin).

  • Actavis buys infectious disease specialist Durata Actavis buys infectious disease specialist Durata

    Cubicin (daptomycin) and Sivextro (tidezolid) and The Medicine Company's Orbactiv (oritavancin) in the ABSSSI category.

  • FDA approves antibacterial skin drug Orbactiv FDA approves antibacterial skin drug Orbactiv

    US regulator authorises Medicines Company's treatment for ABSSSI. The Food and Drug Administration has approved antibacterial drug Orbactiv (oritavancin) to treat adults with acute bacterial skin and skin structure infections

  • Cubist gets green light from FDA for new antibiotic Sivextro Cubist gets green light from FDA for new antibiotic Sivextro

    2020. Other drugs in development to treat ABSSSIs include Furiex Pharmaceuticals' avarofloxacin (phase III), Melinta Therapeutics' delafloxacin (phase III) and The Medicines Company's oritavancin (filed for approval in the US).

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics